Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Melanoma 15Neoplasm Metastasis 12Squamous Cell Carcinoma of Head and Neck 11Lung Neoplasms 11Skin Neoplasms 10Neoplasms 9Ovarian Neoplasms 8Recurrence 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Urinary Bladder Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Basal Cell 6Breast Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Colonic Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Merkel Cell 5Carcinoma 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Stomach Neoplasms 3Sarcoma 3Mycosis Fungoides 3

Interventions

Magnetic Resonance Spectroscopy 9Cyclophosphamide 7X-Rays 6Temozolomide 6Specimen Handling 6Phantoms, Imaging 6Biopsy 6Nuclear Medicine Department, Hospital 5Etoposide 5Nivolumab 4Bevacizumab 4Radiation 3Irinotecan 3Automobiles 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2lutetium Lu 177 dotatate 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2abemaciclib 2Watchful Waiting 2Radiotherapy 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × cemiplimab × 1 year × Clear all
NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡